Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Teva
 More »

  • Teva Cutting 5,000 Jobs in Global Restructuring
    Teva Pharmaceutical Industries said today it will eliminate about 5,000 jobs-10% of its ... end of 2014 under the restructuring, which Teva said will refocus the company on growing ...
    10-10-2013
  • License to Infringe on Research Tool Patents
    ... In these cases, Teva sued Sandoz and Mylan alleging that their use of Teva's patented ... In opposing the motions, Teva argued that the patented polypeptides were not "drug ...
    10-1-2013
  • Top 40 Molecular Millionaires
    ... stock as of April 17 55 Closing price on April 17: $213.08 #8. Philip Frost Chaiman, Teva Pharmaceutical Industries Total value of all shares: $544,686,197 14,587,204 shares as ...
    9-19-2013
  • Otsuka Acquires Astex for $866M
    cell lung cancer (NSCLC) and gastric cancer; OVF (fentanyl citrate), originating with Teva Pharmaceutical Industries and approved in Japan for cancer-related pain; and S-1, an ...
    9-5-2013
  • Spreading Sunshine on What Biopharma Pays Physicians
    ... Besides GSK and Pfizer, Abbott Laboratories, Allergan, AstraZeneca, Cephalon (acquired by Teva Pharmaceutical Industries), Eli Lilly, Novartis, Merck & Co., two divisions of ...
    8-29-2013
  • Teva Declines Right to License Rexahn Cancer Drug
    Teva Pharmaceutical Industries has decided not to exercise its option to license RX-3117, ... License Option (RELO) agreement for RX-3117 between Rexahn and Teva has been terminated. ...
    8-28-2013
  • A License to Infringe on Research Tool Patents
    ... In these cases, Teva sued Sandoz and Mylan alleging that their use of Teva's patented ... In opposing the motions, Teva argued that the patented polypeptides were not "drug ...
    8-22-2013
  • Teva, Perrigo to Launch Generic Temodar
    Teva Pharmaceutical Industries and Perrigo said today they will launch a generic ... Teva said it will manufacture, market, and distribute the product in the United States, ...
    8-12-2013
  • Novo Nordisk Tops GEN List of Top 25 Biotech Companies
    Only two of the top 25 companies on this list-Teva (NYSE:TEVA) and Elan (NYSE:ELN)-saw their share prices decline, in each case following unique challenges that had many of the ...
    7-25-2013
  • Biosimilar Marriage Ends in Divorce for Teva, Lonza
    Teva Pharmaceutical Industries and Lonza Group said today they would end their ... and progress that the joint venture has made to this point," Teva said in a statement. ...
    7-25-2013
  • Rexahn Licenses University of Maryland Cancer Drug Delivery Platform
    linked to uncontrolled tumor growth; RX-3117, a small molecule compound developed with Teva Pharmaceutical Industries that inhibits DNA and RNA synthesis and induces apoptotic ...
    7-17-2013
  • Top 25 Biotech Companies of 2013
    Only two of the top 25 companies on this list (Teva and Elan) saw their share prices ... 49.5% Position on 2012 List: #8 #6. Teva Pharmaceutical Industries 2013 Market Cap: ...
    7-15-2013
  • Latest Biosimilar Guidance Raises More Questions
    ... FDA should also consider Teva Pharmaceuticals' advice to spell out how the agency will ... timelines for the various meetings," Teva stated in a letter from Penny S. Levin, ...
    6-21-2013
  • Teva Snaps Up MicroDose Therapeutx in Up To $165M Deal
    Teva Pharmaceutical Industries is acquiring MicroDose Therapeutx, a pharma and drug ... Teva is slated to acquire all of MicroDose's outstanding shares for $40 million, and will ...
    6-17-2013
  • Cancer's Bitter Medicine
    ... $118,000; Ariad Pharmaceuticals' ponatinib, $138,000; and Teva Pharmaceutical's Synribo (omacetaxine mepesuccinate), a monthly $28,000 for induction and $14,000 for maintenance. ...
    6-15-2013

  • Journal Articles

  • Applications of Human Tissue-Engineered Blood Vessel Models to...
    Maria Pricci, Jean-Michel Bourget, Hubert Robitaille, Chiara Porro, Raffaella Soleti, H. Ahmed Mostefai, François A. Auger, M. Carmen Martinez, Ramaroson Andriantsitohaina, Lucie Germain
    Tissue Engineering, Part A
    The first two were composed of an adventitia (tissue-engineered vascular adventitia (TEVA)... affect superoxide anion (O2-) release in TEVA. MPs enhanced NF-?B expression but did not ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll